Rigel Pharmaceuticals (RIGL) Earnings Analysis
Rigel Pharmaceuticals (RIGL) has no confirmed upcoming earnings date. Last quarter (2026-03-03) it missed with EPS 1.14 USD vs 1.33 USD est (-14.3%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E 1.88.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does RIGL next report earnings?
No confirmed upcoming earnings date is currently scheduled for RIGL. This page updates as the calendar is published.
RIGL earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-03 | 1.14 USD | 1.33 USD | -14.3% | Miss |
| 2025-03-04 | 0.8 USD | 0.3 USD | +166.7% | Beat |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
RIGL valuation and analyst view
| Trailing P/E | 1.88 |
|---|---|
| Trailing EPS | 19.782 USD |
| Price / book | 1.74 |
| Dividend yield | 0.00% |
| Market cap | 0.71B |
| Analyst consensus | Buy (8 buy / 7 hold / 0 sell) |
| Avg price target | 40 USD |
Related research pages
Frequently asked questions
When is Rigel Pharmaceuticals (RIGL)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for RIGL. This page updates as the calendar is published.
Did RIGL beat earnings last quarter?
In its 2026-03-03 report, RIGL posted EPS of 1.14 USD versus a 1.33 USD estimate — a miss of 14.3%.
What is RIGL's earnings track record?
Over the last 2 reported quarters with consensus data, RIGL beat estimates 1 times (50%).
What is RIGL's current P/E ratio and EPS?
RIGL trades at a trailing P/E of 1.88 on trailing EPS of 19.78231588094721 USD.
What do analysts rate RIGL?
Analyst consensus is "Buy" across 15 ratings (0 strong buy, 8 buy, 7 hold, 0 sell, 0 strong sell). Average 12-month price target: 40 USD.